BRAF V600E mutation in mCRC: ~8-10% prevalence, poor prognosis (median OS halved vs BRAF-...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | RF-CRC-BRAF-V600E-POOR-PROGNOSIS |
|---|---|
| Type | Red flag |
| Status | reviewed 2026-04-26 | pending_clinical_signoff |
| Diseases | DIS-CRC |
| Sources | SRC-ESMO-COLON-2024 SRC-NCCN-COLON-2025 |
Red Flag Origin
| Definition | BRAF V600E mutation in mCRC: ~8-10% prevalence, poor prognosis (median OS halved vs BRAF-WT on standard chemo). Cetuximab/panitumumab ineffective. Encorafenib + cetuximab (BEACON CRC) is preferred 2L+; some 1L data favor FOLFOXIRI + bev intensification in MSS BRAF-mutant. |
|---|---|
| Clinical direction | intensify |
| Category | high-risk-biology |
Trigger Logic
{
"any_of": [
{
"finding": "braf_v600e_mutation",
"value": true
}
],
"type": "biomarker"
}
Notes
~30% of BRAF-mutant CRC are MSI-H — RF-CRC-MSI-H-ACTIONABILITY takes precedence (immunotherapy-track outranks chemo-intensification). In MSS BRAF-V600E mutants (the harder subgroup), TRIBE-2 / FOLFOXIRI+bev has ORR 56% but inferior to immunotherapy combinations under study.
Used By
Algorithms
ALGO-CRC-METASTATIC-1L- ALGO-CRC-METASTATIC-1LALGO-CRC-METASTATIC-2L- ALGO-CRC-METASTATIC-2L
Indications
IND-CRC-METASTATIC-1L-RAS-WT-LEFT- IND-CRC-METASTATIC-1L-RAS-WT-LEFT